Gastric Cancer - Pipeline Review, H2 2015

Description: Gastric Cancer - Pipeline Review, H2 2015

Summary

The report ‘Gastric Cancer - Pipeline Review, H2 2015’, provides an overview of the Gastric Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastric Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastric Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastric Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

Introduction

Gastric Cancer Overview

Therapeutics Development

Gastric Cancer - Therapeutics under Development by Companies

Gastric Cancer - Therapeutics under Investigation by Universities/Institutes

Gastric Cancer - Pipeline Products Glance

Gastric Cancer - Products under Development by Companies

Gastric Cancer - Products under Investigation by Universities/Institutes

Gastric Cancer - Companies Involved in Therapeutics Development

Gastric Cancer - Therapeutics Assessment

Drug Profiles

Gastric Cancer - Recent Pipeline Updates

Gastric Cancer - Dormant Projects

Gastric Cancer - Discontinued Products

Gastric Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Gastric Cancer, H2 2015

Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Development by Companies, H2 2015 (Contd..1)

Number of Products under Development by Companies, H2 2015 (Contd..2)

Number of Products under Development by Companies, H2 2015 (Contd..3)

Number of Products under Development by Companies, H2 2015 (Contd..4)

Number of Products under Development by Companies, H2 2015 (Contd..5)

Number of Products under Development by Companies, H2 2015 (Contd..6)

Number of Products under Development by Companies, H2 2015 (Contd..7)

Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Investigation by Universities/Institutes, H2 2015
Gastric Cancer - Pipeline by AB Science SA, H2 2015
Gastric Cancer - Pipeline by AbbVie Inc., H2 2015
Gastric Cancer - Pipeline by AbGenomics International, Inc., H2 2015
Gastric Cancer - Pipeline by Advaxis, Inc., H2 2015
Gastric Cancer - Pipeline by Ambrx, Inc., H2 2015
Gastric Cancer - Pipeline by Amgen Inc., H2 2015
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015
Gastric Cancer - Pipeline by Astellas Pharma Inc., H2 2015
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Galaxy Biotech, LLC, H2 2015
Gastric Cancer - Pipeline by Galena Biopharma, Inc., H2 2015
Gastric Cancer - Pipeline by Genelux Corporation, H2 2015
Gastric Cancer - Pipeline by Genentech, Inc., H2 2015
Gastric Cancer - Pipeline by Gilead Sciences, Inc., H2 2015
Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Gastric Cancer - Pipeline by GlycoNex Inc., H2 2015
Gastric Cancer - Pipeline by Glycotope GmbH, H2 2015
Gastric Cancer - Pipeline by Green Cross Corporation, H2 2015
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015
Gastric Cancer - Pipeline by Ignyta, Inc., H2 2015
Gastric Cancer - Pipeline by ImmunoGen, Inc., H2 2015
Gastric Cancer - Pipeline by Immunomedics, Inc., H2 2015
Gastric Cancer - Pipeline by Incyte Corporation, H2 2015
Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Intezyne, Inc, H2 2015
Gastric Cancer - Pipeline by ISU ABXIS Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Johnson & Johnson, H2 2015
Gastric Cancer - Pipeline by Kadmon Corporation, LLC, H2 2015
Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H2 2015
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Gastric Cancer - Pipeline by LegoChem Biosciences, Inc, H2 2015
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2015
Gastric Cancer - Pipeline by MacroGenics, Inc., H2 2015
Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Merck & Co., Inc., H2 2015
Gastric Cancer - Pipeline by Merck KGaA, H2 2015
Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2015
Gastric Cancer - Pipeline by MSM Protein Technologies, Inc., H2 2015
Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2015
Gastric Cancer - Pipeline by NeoPharm Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Novartis AG, H2 2015
Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015
Gastric Cancer - Pipeline by Oncobiologics, Inc., H2 2015
Gastric Cancer - Pipeline by Oncolytix Biopharma Inc., H2 2015
Gastric Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015
Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H2 2015
Gastric Cancer - Pipeline by Oncothyreon Inc., H2 2015
Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Panacea Biotec Limited, H2 2015
Gastric Cancer - Pipeline by Patrys Limited, H2 2015
Gastric Cancer - Pipeline by Pfizer Inc., H2 2015
Gastric Cancer - Pipeline by Pharma Mar, S.A., H2 2015
Gastric Cancer - Pipeline by Pharmacyclics, Inc., H2 2015
Gastric Cancer - Pipeline by Priaxon AG, H2 2015
Gastric Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H2 2015
Gastric Cancer - Pipeline by Sanofi, H2 2015
Gastric Cancer - Pipeline by Sareum Holdings Plc, H2 2015
Gastric Cancer - Pipeline by Sequella, Inc., H2 2015
Gastric Cancer - Pipeline by Siena Biotech S.p.A., H2 2015
Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Supratek Pharma Inc., H2 2015
Gastric Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Gastric Cancer - Pipeline by Synthon Holdings BV, H2 2015
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Takis S.r.l., H2 2015
Gastric Cancer - Pipeline by Teikoku Pharma USA, Inc., H2 2015
Gastric Cancer - Pipeline by Tesaro, Inc., H2 2015
Gastric Cancer - Pipeline by Transgene SA, H2 2015
Gastric Cancer - Pipeline by Vaxon Biotech, H2 2015
Gastric Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Zymeworks Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Gastric Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Gastric Cancer - Dormant Projects, H2 2015
Gastric Cancer - Dormant Projects (Contd..2), H2 2015
Gastric Cancer - Dormant Projects (Contd..4), H2 2015
Gastric Cancer - Dormant Projects (Contd..6), H2 2015
Gastric Cancer - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Gastric Cancer, H2 2015
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3422678/](http://www.researchandmarkets.com/reports/3422678/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Gastric Cancer - Pipeline Review, H2 2015
- **Web Address:** http://www.researchandmarkets.com/reports/3422678/
- **Office Code:** SCD22DWL

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

- **Title:** Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
- **First Name:** ___________________________  **Last Name:** ___________________________
- **Email Address:** * ___________________________
- **Job Title:** ___________________________
- **Organisation:** ___________________________
- **Address:** ___________________________
- **City:** ___________________________
- **Postal / Zip Code:** ___________________________
- **Country:** ___________________________
- **Phone Number:** ___________________________
- **Fax Number:** ___________________________

*Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)*
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World